Mazdutide approved in US in 2025
2
Ṁ45
Dec 31
38%
chance

Mazdutide, a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and Eli Lilly, has shown promising results in weight management. It received approval from China's NMPA in June 2025. This market predicts whether the FDA will approve mazdutide for weight management in the U.S. before December 22, 2025. Resolution will be based on official FDA announcements.

Get
Ṁ1,000
and
S3.00
© Manifold Markets, Inc.Terms + Mana-only TermsPrivacyRules